The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by
Alan B. Colowick, MD, MPH
Advertisement
Articles by Alan B. Colowick, MD, MPH
Advertisement
Latest Updated Articles
- Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia
Published: October 1st 2002 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
4
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
5
